ArticleClinical and experimental reproductive medicine2026
Quercetin attenuates nicotine-induced ovarian and uterine dysfunction in rats.
Article in Clinical and experimental reproductive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveNicotine, a principal constituent of tobacco smoke, disrupts female reproductive physiology. Quercetin, a flavonoid with both phytoestrogenic and antioxidant properties, may counteract this toxicity. This study aimed to evaluate the histological, biochemical, and molecular effects of quercetin co-administration with nicotine on ovarian and uterine tissues in rats.
methodsThirty-two female Wistar rats were assigned to four groups: control, nicotine-treated (1 mg/kg), quercetin-treated (15 mg/kg), and a combined nicotine (1 mg/kg)-quercetin (15 mg/kg) group. Histopathological assessments were performed alongside biochemical analyses of oxidative stress markers-malondialdehyde (MDA), superoxide dismutase (SOD), and total antioxidant capacity (TAC)-and enzyme-linked immunosorbent assay (ELISA)-based hormonal profiling. Immunohistochemistry was employed to quantify estrogen receptor-alpha (ERα) and Ki-67 expression.
resultsCo-administration of nicotine and quercetin increased uterine wall thickness and was associated with elevated estradiol levels, reduced MDA activity, and increased SOD and TAC in both uterine and ovarian tissues compared with the nicotine group. The nicotine-quercetin group also showed a lower Ki-67 index in ovarian follicles and stroma, along with a marked reduction in atretic follicles. Conversely, there were significant increases in antral follicles, corpus luteum formation, and ERα expression in the uterine endometrium and epithelium, as well as in the ovarian stroma and corpus luteum, versus the nicotine-only group.
conclusionQuercetin (15 mg/kg) appears to protect against nicotine-induced reproductive impairments (1 mg/kg), likely through its antioxidant properties, its capacity to stabilize hormone levels, and its modulation of ERα and Ki-67 expression. These findings support quercetin's therapeutic potential for preventing or alleviating smoking-related reproductive damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.